Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-12-20
2009-12-01
Shiao, Rei-Tsang (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S317000, C514S332000, C514S361000, C514S370000, C514S383000, C514S396000, C514S447000, C514S461000, C544S330000, C546S194000, C546S309000, C548S134000, C548S146000, C548S262600, C548S328100, C549S063000, C549S480000
Reexamination Certificate
active
07625914
ABSTRACT:
Novel compounds having the general formula (I) below:are useful in a wide variety of applications in human or veterinary medicine (in dermatology, and also in the fields of cardiovascular diseases, immune diseases and/or diseases associated with lipid metabolism), or, alternatively are formulated into cosmetic compositions.
REFERENCES:
patent: 6927228 (2005-08-01), Bernardon et al.
patent: 1 216 980 (2002-06-01), None
patent: 02/12210 (2002-02-01), None
patent: WO 0212210 (2002-02-01), None
patent: 2004/024939 (2004-03-01), None
Patani et al. “Bioisosterism: A Rational Approach in Drug Design” Chemical Reviews, 1996, vol. 96, pp. 3147-3176.
M.M.T. Downie et al., “Peroxisome proliferator-activated receptor and farnesoid X receptor ligands differentially regulate sebaceous differentiation in human sebaceous gland organ cultures in vitro”, British Journal of Dermatology, 2004: 151: 766-775, published by Blackwell Publishing, UK.
Ramona Behshad et al., “A Retrospective Case Series Review of the Peroxisome Proliferator-Activated Receptor Ligand Rosiglitazone in the Treatment of Atopic Dermatitis,” Arch Dermatol. 2008; 144(1):84-88, published by AMA, Chicago, IL, US.
Tamar Nijsten et al,, “Peroxisome proliferator-activated receptors in squamous cell carcinoma and its precursors,” Journal of Cutaneous Pathology, 2005: 32:340-347, published by Blackwell Munksgaard, Denmark.
Joong Sun Lee et al., “PPAR-gamma agonist, ciglitazone, increases pigmentation and migration of human melanocytes,” Experimental Dermatology, 2007, 16, 118-123, published by Blackwell Munksgaard, Denmark.
James Varani et al. “Thiazolidinediones: potential as therapeutics for psoriasis and perhaps other hyperproliferative skin disease,” Expert Opin. Investig. Drugs, 2006, 15(11):1453-1468, published by Informa HealthCare, UK.
Aubert Jerome
Chantalat Laurent
Clary Laurence
Rivier Michel
Thoreau Etienne
Buchanan Ingersoll & Rooney P.C.
Galderma Research & Development
Kosack Joseph R
Shiao Rei-Tsang
LandOfFree
Compounds that modulate PPARγ type receptors and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds that modulate PPARγ type receptors and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds that modulate PPARγ type receptors and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4127899